Updates on HER2-Directed ADCs Across Solid Tumors - Episode 5

ADCs Targeting GI Cancers

, , , ,

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Assessing HER2 Status Across Tumor Types
    EP. 2: ADCs Targeting HER2+ Breast Cancer
    EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
    EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
    Now Viewing
    EP. 5: ADCs Targeting GI Cancers
    EP. 6: ADCs Targeting HER2+ Lung Cancer
    EP. 7: Impact of ADCs on Brain Metastases
    EP. 8: ADCs Targeting HER2+ GU Cancers
    EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
    EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
    EP. 11: Managing ILD and Pneumonitis Risk From ADCs
    EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
    EP. 13: Managing Hematologic AEs Associated with ADC Treatments
    EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
    EP. 15: ADC Sequencing
    EP. 16: Emerging ADCs in Development
    EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
    EP. 18: The Future for HER2-Directed ADCs
    EP. 19: Key Takeaways and Closing Thoughts on ADCs

    Video content above is prompted by the following:

    • Please review the data for T-DM1 for:
      • HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
      • T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
    • Please review the data for T-DXd for:
      • HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
      • Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
      • HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
      • Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
    • What is the potential for HER2-targeting ADCs in other GI cancers?
      • Biliary Tract Cancers, Pancreatic
        • PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
        • HERB trial (BTC): Ohba_ASCO2022
    • Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
    • Is there an unmet need ADCs could help fill?

    x